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Background: Asthma has a higher prevalence in athlete populations such as Olympic athletes than in the
general population. Correct diagnosis and management of asthma in athletes is important for symptom
control and avoidance of doping accusations. However, few reports are available on asthma treatment in
the athlete population in clinical practice. In this study, we focused on the clinical efﬁcacy of inhaled
corticosteroid (ICS) for asthma in a Japanese athlete population.
Methods: The study subjects included athletes who visited the Niigata Institute for Health and Sports
Medicine, Niigata, Japan for athletic tests and who were diagnosed with asthma on the basis of respi-
ratory symptoms and positive results in a bronchodilator or bronchial provocation test such as exercise,
hypertonic saline, or methacholine provocation. The athletes received ICS alone for at least 3 months, and
the clinical background, sports type, and treatment efﬁcacy were analyzed.
Results: The study population comprised 80 athletes (59 men and 21 women) with a median age of 16.0
years. Regarding sports type, 28 athletes engaged in winter sports (35%), 22 in endurance sports (27.5%),
and 25 in indoor sports (31.3%). Although ICS is the primary treatment in athlete asthma, 16.3% of the
athletes showed an unsatisfactory response to treatment according to the Global Evaluation of Treatment
Effectiveness (GETE). These subjects were characterized by a decreased response to methacholine and
lower values for FEV1/FVC and type 2 helper T cell (Th2)-associated biomarkers relative to responsive
athletes. In multivariate analysis, FEV1/FVC and the logarithm to the base 10 of the IgE level were
independently associated with the ICS response.
Conclusions: These data suggest that ICS is effective for asthma in most athletes. However, certain
asthmatic athletes are less responsive to ICS than expected. The pathogenesis in these subjects may differ
from that of conventional asthma characterized by chronic allergic airway inﬂammation.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Exercise is well established as one of the factors associated with
asthma exacerbation, and approximately 70e80% of asthma patients
experience exercise-induced bronchoconstriction (EIB).1 A higheredicine, Department of Ho-
logical Functions and Medical
l and Dental Sciences, 1-754
510, Japan.
a).
ety of Allergology.
rgology. Production and hosting by Elsprevalence of bronchial asthma has been reported in athletes than in
the general population. The percentage of Olympic athletes diag-
nosed with asthma by a bronchial dilatation test or provocation test
was 21.2% (2000) and 20.7% (2004), respectively, which was signif-
icantly higher than the rate in the general population.2,3 Several
reports describe an increased risk of developing airway hyper-
responsiveness (AHR) in cross-country skiers, swimmers, and
skaters.4,5 Another investigation reported that endurance sports
such as cycling and marathon running, which require substantial
increases in ventilation, are high-risk sports for developing AHR.6,7
Inhaled corticosteroid (ICS) treatment is recommended for
management of asthma in the athlete population as well as in theevier B.V. All rights reserved.
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therapy with ciclesonide (CIC), a new ICS administered once daily
as a pro-drug type, is more effective for symptom control and
reduction of fraction of exhaled nitric oxide (FeNO) than mono-
therapy with montelukast, a leukotriene modiﬁer administered
once daily.9 Another study showed minimal effects of ICS in
amelioration of respiratory symptoms and AHR to methacholine in
cross-country skiers.10 However, few reports have analyzed asthma
treatment in the athlete population in clinical practice.
In practice, asthma is diagnosed on the basis of at least one
symptom such as dyspnea, cough, chest tightness, or stridor;
obstructive impairment of lung function reversible by a broncho-
dilator; bronchial hypersensitivity; and evidence of airway allergic
inﬂammation (such as sputum eosinophilia and high FeNO). The
International Olympic Committee (IOC) Medical Commission has
provided guidelines on the diagnosis and management of asthma
and EIB in athletes.11 Bronchial provocation tests are highly rec-
ommended for diagnosis of asthma and EIB not only to support the
health of athletes but also to avoid doping allegations.
Few data are available regarding responses to ICS for asthma in
the athlete population. To clarify the therapeutic effects of ICS
against athlete asthma, we conducted a retrospective review of the
effects of ICS in Japanese athletes with asthmawhowere positive in
at least one bronchial provocation test. The subjects were evaluated
according to improvement of clinical symptoms, pulmonary func-
tion parameters, and FeNO. We conducted comparisons among
sports types and between ICS responders and non-responders.
Methods
Subjects
Eighty athletes (59 men) who were nonsmokers and diagnosed
with asthma at the Niigata Institute for Health and Sports Medicine
were enrolled in this retrospective analysis. Athletes with respira-
tory symptoms as well as positive ﬁndings on a bronchodilator test
or bronchial provocation test such as methacholine, exercise, or
hypersaline provocation were diagnosed as asthmatic. Athletes in
this study were deﬁned as people who were competitive at the
regional to national level and trained approximately 20 h/week.
Sport activities were categorized as endurance/non-endurance,
winter/summer, and indoor/outdoor sports according to the work
of Alatanta et al.12 This studywas performed in accordancewith the
Ethical Principles for Medical Research Involving Human Subjects,
Declaration of Helsinki, and with the approval of the Ethics Com-
mittee of Niigata Institute for Health and Sports Medicine.
Study
Before the start of ICS treatment, all subjects underwent phys-
ical examination; pulmonary function testing; fraction of exhaled
nitric oxide (FeNO); peripheral blood eosinophil count; sputum
eosinophil count (if possible); total IgE; and a radioallergosorbent
test (RAST) for mite, ragweed, and cedar pollen. Pulmonary func-
tion testing was performed using a spirometer (SpiroSift SP-470;
Fukuda Denshi, Tokyo, Japan) in accordance with the ATS guide-
lines.13 In the bronchodilator test, a positive response was deﬁned
as an increase of at least 12% in FEV1 and 200mL above the baseline
value after inhalation of salbutamol (200 mg). FeNO was measured
using an NO analyzer (Kimoto Denshi, Osaka, Japan) with the on-
line method; the method of measuring FeNO conformed to a pre-
vious mutual consensus statement from the ATS/ERS.14
Subjects whowere treatedwith ICS alone at a dose equivalent to
400 (<15 years of age) or 800 (15 years of age) mg/day of bude-
sonide for at least 3 months were enrolled in this study. Clinicalsymptoms, results of pulmonary function testing, and FeNO after
ICS treatment were compared with those at baseline.
Assessment
The response to ICS was assessed using the physician's Global
Evaluation of Treatment Effectiveness (GETE),15,16 an overall clinical
evaluation of asthma control from 12 to 24 weeks, based on all
available information including patient interview and physical ex-
amination. In the GETE, treatment is rated as excellent (complete
control of asthma), good (marked improvement of asthma), mod-
erate (discernible but limited improvement of asthma), poor (no
appreciable change in asthma symptoms), or worsening of asthma.
Subjects with excellent, good, and moderate responses were
considered responders.
Bronchial provocation tests
The methacholine challenge involved 2 min of tidal breathing of
methacholine, and the concentration of methacholine that pro-
voked a 20% or more decrease in FEV1 (PC20) was determined.17 A
PC20 of 8 mg/mL was deﬁned as a positive response in this study.
EIB was diagnosed as previously described.17 Brieﬂy, the athletes
were instructed to run for 8 min at submaximal exercise intensity
on a motor-driven treadmill. FEV1 was measured before running
and 3, 5, 10, 15, and 20 min after running. A 10% decrease in FEV1
relative to the value before exercise was deﬁned as a positive
response. The hypertonic saline challenge was performed as
described previously.18 Brieﬂy, hyperosmolar saline (4.5%) was
inhaled during tidal breathing as a wet aerosol generated by a
large-volume ultrasonic nebulizer. FEV1 was measured before
inhalation and 3, 5, 10, 15, and 20 min after inhalation. A 15%
decrease in FEV1 relative to the value before inhalationwas deﬁned
as a positive response.
Statistical analysis
The results were expressed as mean (±SD) in normally distrib-
uted data and as medians (25the75th interquartile range) in non-
normally distributed data for continuous variables. The differ-
ences between dichotomous variables were analyzed by Fisher's
exact test or ManneWhitney U test. The in-group (pre- and post-
treatment) comparisons were made using Wilcoxon's signed-rank
test. Multivariate analysis was used to identify the variables that
inﬂuenced the ICS response. The data for FeNO, PC20, IgE, and blood
eosinophil count became normally distributed after log trans-
formation. Variables that were statistically signiﬁcant in the
dichotomous analysis were ﬁrst applied in stepwise selection
because of strong correlation among the values of FeNO, PC20, IgE,
and blood eosinophil count. All variables that correlated at p < 0.20
in stepwise selection were applied in multivariable logistic
regression analysis. All statistical analyses were performed using
JMP statistical software (JMP 10.0; SAS Institute Inc., Cary, NC, USA).
In all statistical analyses, p < 0.05 was considered signiﬁcant.
Results
Eighty athletes who had a positive response to a bronchodilator
or bronchial provocation test were analyzed in this study. The
baseline data of all subjects are shown in Table 1. The distribution of
sports type was 35.0% in winter sports, 27.5% in endurance sports,
and 31.3% in indoor sports. The baseline data of each sport type
were not apparently different (data not shown). Approximately half
of the subjects were diagnosed with asthma by the methacholine
provocation test. The GETE assessment was collected from all
Table 1
Clinical characteristics.
Sex (M/F) (n) 59/21
Age (yr) median (25the75th quartile) 16.0 (15e17)
Sports
Winter (%) 35.0
Endurance (%) 27.5
Indoor (%) 31.3
Provocation test
Bronchodilator (%) 18.8
Methacholine (%) 53.8
Exercise (%) 22.5
Hyperosmolarity (%) 16.3
Asthma in childhood (%) 58.2
Allergic rhinitis (%) 64.6
Log10 serum total IgE (IU/L) mean (SD) 2.38 (0.74)
Positive rate of mite-speciﬁc IgE (%) 67.5
Positive rate of cedar pollen-speciﬁc IgE (%) 54.5
Positive rate of ragweed-speciﬁc IgE (%) 14.3
Log10 blood eosinophils (/uL) mean (SD) 2.32 (0.36)
Sputum eosinophils (%) median (25the75th quartile) 4.6 (2.2e18.4)
Log10 FeNO (ppb) mean (SD) 1.65 (0.43)
%FEV1 (%) mean (SD) 92.1 (12.3)
FEV1/FVC (%) mean (SD) 83.9 (8.4)
%MMF (%) mean (SD) 90.9 (25.7)
ICS (mg/d) median (25the75th quartile)
(equivalent to budesonide)
800 (800e800)
Treatment duration (days) median (25the75th quartile) 147 (112e196)
GETE (excellent/good/moderate/poor/worsening) (n) 15/37/15/11/2
FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; MMF, maximum mid expiratory ﬂow rate; ICS, inhaled corti-
costeroid; GETE, global evaluation of treatment effectiveness.
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tients were considered responders to ICS (excellent, 18.8%; good,
46.2%; moderate, 18.8%) and 16.2% non-responders (poor, 13.7%;
worsening, 2.5%).
In Table 2, the changes in the indices after ICS therapy are
compared according to the results of the GETE. In the responders to
ICS, logarithm to the base 10 (log10) FeNO (pretreatment:
1.69 ± 0.43 ppb; posttreatment: 1.49 ± 0.32 ppb; p < 0.0001), FEV1
(% predicted) (91.4% ± 12.6%, 95.9% ± 12.9%; p ¼ 0.0002), FEV1/FVC
(84.9% ± 8.4%, 86.8% ± 7.5%; p ¼ 0.0027), and MMEF (% predicted)
(91.4% ± 24.0%, 101.5 ± 28.4%; p ¼ 0.0003) signiﬁcantly improved
after treatment, whereas there were no signiﬁcant changes after
treatment in non-responders to ICS (Table 2). Among sports types,
there were no differences in GETE results, changes of respiratory
functions, or log10 FeNO (data not shown).
Athletes with an effective clinical response to ICS displayed
higher values than athletes with an ineffective response to ICS in
the following parameters: Th2-associated biomarkers such as
serum total IgE, blood eosinophil count, and FeNO (log10 IgE: re-
sponders versus non-responders, 2.51 ± 0.71 IU/L versus
1.61 ± 0.63 IU/L, p < 0.0001; log10 eosinophil count: 2.37 ± 0.36/mL
versus 2.08 ± 0.34/mL, p ¼ 0.0181; log10 FeNO: 1.69 ± 0.43 ppb
versus 1.40 ± 0.39 ppb, p¼ 0.0411), as well as FEV1/FVC (responders
versus non-responders, 85.0% ± 8.2% versus 77.9% ± 7.2%,Table 2
Summary of groups for response to ICS treatment.
Responder (65)
Pretreatment Posttreatment p value
Log10 FeNO (ppb) 1.69 (0.43) 1.49 (0.32) p < 0.0001**
%FEV (%) 91.4 (12.6) 95.9 (12.9) p ¼ 0.0002**
FEV/FVC (%) 84.9 (8.4) 86.8 (7.5) p ¼ 0.0027*
%MMF (%) 91.4 (24.0) 101.5 (28.4) p ¼ 0.0003**
FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced
Data express mean (SD) or median (25the75th quartile). Asterisks indicate signiﬁcancep ¼ 0.0053). In addition, responders had lower logarithm to the
base 2 (log2) PC20 values than non-responders (responders versus
non-responders, 0.09 ± 1.37 mg/mL versus 1.28 ± 1.06 mg/mL,
p ¼ 0.0200). In sputum eosinophils, the data exhibited high vari-
ability; therefore, signiﬁcant differences were not observed among
groups. There were negligible differences in treatment duration
and ICS dose (Table 3).
To identify the variables that inﬂuenced the ICS response, we
performed multivariate statistical analysis. Firstly, the variables
that were statistically signiﬁcant in the dichotomous analysis were
applied in stepwise selection because the data of log10 FeNO, log10
IgE, log2 PC20, and log10 eosinophil count were strongly correlated
with each other. The stepwise selection revealed that FEV1/FVC and
log10 IgE were useful independent variables. According to multi-
variate logistic analysis, both FEV1/FVC (odds ratio (OR), 1.14; 95%
conﬁdence interval (95% CI), 1.04e1.28; p ¼ 0.0048) and log10 IgE
(OR, 5.71; 95% CI, 2.24e18.40; p ¼ 0.0001) were identiﬁed as in-
dependent factors with a signiﬁcant association with the ICS
response (Table 4).
Discussion
Although many reports have described a higher prevalence of
asthma in the athlete population, detailed investigations on the
pharmacological management of asthma in athletes are lacking.We
previously reported that ciclesonide, as a once-daily pro-drug ICS,
was superior for improvement of symptoms, pulmonary function,
and FeNO relative to the leukotriene modiﬁer, montelukast.9 In this
study, we retrospectively investigated the effects of ICS and dif-
ferences between ICS responders and non-responders among Jap-
anese athletes diagnosed with asthma by a bronchodilator or
bronchial provocation test. Although this study was retrospective
in design and may thus be affected by variable dosing of ICS, po-
tential effects of non-adherence, or lack of randomization, this is
the ﬁrst report to analyze the ICS response in an athlete population
in a practical setting.
ICS is the most effective drug for long-term control of asthma
and prevention of EIB.19 The guidelines for management of asthma
in athletes also describe ICS as a ﬁrst-line agent.20 In subjects with
airway inﬂammation consistent with asthma, the beneﬁt of ICS
treatment in reducing the severity of EIB is well established.21
However, the only long-term study performed in athletes with
EIB suggests that daily treatment with ICS does not have any
beneﬁcial effect on respiratory symptoms or AHR to methacho-
line.10 In this study, ICS was effective in most of the athletes for
amelioration of clinical symptoms, reduction of FeNO values, and
improvement of pulmonary function parameters. However,
approximately 15% of the athletes were not responsive to ICS.
Previous reports and the data of the present study indicate that the
phenotypes of asthma in the athlete population are
heterogenous.22e24
In the athletes in this study, a positive response to ICS was
associated with higher IgE and higher FEV1/FVC in multivariateNon-responder (15)
Pretreatment Posttreatment p value
Log10 FeNO (ppb) 1.40 (0.39) 1.55 (0.30) p ¼ 0.1264
%FEV (%) 95.5 (12.6) 91.3 (9.5) p ¼ 0.1598
FEV/FVC (%) 77.6 (8.2) 80.0 (7.8) p ¼ 0.1763
%MMF (%) 83.6 (33.5) 79.9 (29.5) p ¼ 0.5669
vital capacity; MMF, maximum mid expiratory ﬂow rate.
between pretreatment and posttreatment (*p < 0.05, **p < 0.001).
Table 3
Summary of responder and non-responder to ICS treatment.
Responder Non-Responder p value
Sex (M/F) 47/20 12/1 p ¼ 0.1665
Age (yr) median
(25the75th quartile)
16.0
(15.0e17.0)
16.0
(15.0e17.5)
p ¼ 0.1619
Winter (%) 36.9 30.8 p ¼ 0.7607
Endurance (%) 22.4 23.1 p ¼ 1.0000
Outside (%) 71.6 53.8 p ¼ 0.3260
Symptom at rest (%) 17.9 23.1 p ¼ 0.7018
Symptom on exercise (%) 91.0 69.2 p ¼ 0.0517
Asthma in childhood (%) 60.6 46.2 p ¼ 0.3699
Allergic rhinitis (%) 68.2 46.2 p ¼ 0.2030
Log10 IgE (IU/L) mean (SD) 2.51 (0.71) 1.61 (0.63) p < 0.0001*
Positive rate of
mite-speciﬁc IgE (%)
73.4 38.5 p ¼ 0.0222*
Positive rate of cedar
pollen-speciﬁc IgE (%)
60.9 23.1 p ¼ 0.0159*
Positive rate of
ragweed-speciﬁc IgE (%)
15.6 7.7 p ¼ 0.6785
Log10 eosinophil count
(/uL) mean (SD)
2.37 (0.36) 2.08 (0.34) p ¼ 0.0181*
Sputum eosinophils (%)
median (25the75th quartile)
5.9 (2.8e18.8) 1.1 (0.0e2.6) p ¼ 0.2704
Log10 FeNO (ppb) mean (SD) 1.69 (0.43) 1.40 (0.39) p ¼ 0.0411*
Log2 PC20 (mg/mL) mean (SD) 0.09 (1.37) 1.28 (1.06) p ¼ 0.0200*
%FEV1 (%) mean (SD) 91.4 (12.2) 88.1 (13.3) p ¼ 0.3146
FEV1/FVC (%) mean (SD) 85.0 (8.2) 77.9 (7.2) p ¼ 0.0053*
%MMF (%) mean (SD) 92.7 (24.4) 81.4 (30.0) p ¼ 0.1490
Treatment duration
(days) median
(25the75th quartile)
147.0
(112.0e185.0)
168.0
(124.5e223.5)
p ¼ 0.2137
ICS (mg/d) mean
(25the75th quartile)
800.0
(800e800)
800.0
(800e800)
p ¼ 0.8940
FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; MMF, maximum mid expiratory ﬂow rate; PC20, provocative
concentration causing a 20% fall in FEV1; ICS, inhaled corticosteroid.
Data express mean (SD) or median (25the75th quartile). Asterisks indicate signif-
icance between responder and non-responder(*p < 0.05).
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described that the response to steroid therapy in asthma patients is
associated with IgE level.25 Hyperresponsiveness to methacho-
line,26 the levels of FeNO,27,28 and eosinophil count in peripheral
blood25 have also been reported as predictors of the response to
ICS. In the present study, the values of FeNO, IgE, PC20, and blood
eosinophil count were mutually correlated, so these parameters
were possible confounding factors. Interestingly, our data indicated
that subjects with higher FEV1/FVC were more responsive to ICS,
whereas previous studies reported that severe obstructive impair-
ment of pulmonary function was a predictive factor for the
response to ICS.29,30 Although the odds ratio of FEV1/FVC indicates a
slight contribution, this parameter deﬁnitely plays a role in ICS
response. These data may reﬂect discordance between airway
allergic inﬂammation and airway obstruction in asthma in the
athlete population.
We described the characteristics of non-responders to ICS,
which included lower levels of Th2-associated biomarkers, lower
FEV1/FVC, and mild airway hyperresponsiveness. These character-
istics are also seen in the non-athlete adult population; however,
they are often complicated with COPD or obesity, which wereTable 4
Multivariate logistic analysis of ICS response in FEV1/FVC and log10 IgE.
Odds ratio (95% conﬁdence interval) p value
FEV1/FVC 1.14 (1.04e1.28) 0.0048*
Log10 IgE 5.71 (2.24e18.40) 0.0001*
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. Asterisks indicate
signiﬁcance (*p < 0.05).unlikely in our population. Recently, some reports have described
that the pathophysiological mechanisms of athlete asthma involve
airway epithelial damage and mechanical stress caused by hyper-
pnea.4,22,24 The onset of asthma after starting strenuous exercises
and the non-allergic phenotype appeared to be clinically important
for distinguishing the patients from those with conventional
allergic asthma. However, there were no any differences in the
prevalence of childhood asthma and allergic rhinitis in this study.
In this study, the GETE rating was used to classify subjects as
responders or non-responders to ICS. Certain previous studies
classiﬁed subjects as responders if the GETE rating was excellent or
good.15,16 In our study, subjects with excellent, good, and moderate
GETE ratings were classiﬁed as responders because the aim of this
study was to identify and investigate the population in which ICS
was not at all effective. However, precise evaluation of the
responsiveness to ICS might have been limited by the use of the
GETE for the assessment. In previous studies, the proportion of ICS
responders was reported as 40e60%29e31 in the non-athlete pop-
ulation, whereas our study reported a proportion of 85%. These
discrepancies may have resulted from differences in the deﬁnition
of ICS responders. In the previous studies, subjects with an
improvement in FEV1 of 5e7.5% compared with that before treat-
ment were considered responders. In contrast, we only determined
the results on the basis of the GETE rating.
Subjects in this study were exclusively athletes diagnosed with
asthma by the bronchodilator or bronchial provocation test. The
International Olympic Committee (IOC) medical conference has
highly recommended the bronchial provocation test for diagnosis
of asthma considering anti-doping strategies and athlete health.11
Certain athletes, particularly in winter sports, display discrep-
ancies between clinical symptoms and airway hyper-
responsiveness; that is, they have certain symptoms of asthma
without airway hyperresponsiveness.5 In another study, 61% of EIB-
positive athletes and 45% of normal pulmonary function athletes
reported symptoms related to EIB _ENREF_33.32 According to these
data, self-reported symptoms are unlikely reliable for diagnosis of
asthma in athletes.
In summary, we conducted a retrospective analysis of ICS
treatment in Japanese athletes with asthma. Most of the athletes
showed better control of symptoms, improved pulmonary function
parameters, and decreased FeNO value. However, certain athletes
showed a minimal response to ICS clinically, in addition to lower
Th2-associated biomarker levels, lower FEV1/FVC, and higher PC20.
In multivariate statistics, FEV1/FVC and log10 IgE were indepen-
dently associatedwith the ICS response. These data suggest that the
phenotypes of asthma among athletes are heterogenous, and the
pathogenesis in the subtype that does not respond to ICS may differ
from that of typical chronic allergic airway inﬂammation.
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